Main content

    Prostate Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Metastatic Prostate Cancer  |  Non-Metastatic Prostate Cancer


    Active Trials

    Metastatic Prostate Cancer

    Title: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMb
    Description: This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide alone in participants with mCRPC after failure of an androgen synthesis inhibitor (e.g., abiraterone) and failure of, ineligibility for, or refusal of a taxane regimen.
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older, who have a histologically confirmed, castrate-resistant adenocarcinoma of the prostate
    Status: Active and open to enrollment
    Contact: Andrea Davila, 415-600-1544, Email: DavilaA2@cpmcri.org about Study Genentech CO39385

    Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
    Description: The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC)
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older, who have a histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell features
    Status: Active and open to enrollment
    Contact: Andrea Davila, 415-600-1544, Email: DavilaA2@cpmcri.org about Study Genentech CO39303

    Title: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
    Description: The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older, who have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
    Status: Active and open to enrollment
    Contact: Leslie Corona, 415-600-5766, Email: CoronaLA@cpmcri.org about Study Clovis CO-338-052

    Title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
    Description: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC)
    Investigator: Ari Baron, MD
    Eligibility: Male subjects 18 y/o and older with a histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
    Status: Active and open to enrollment
    Contact: Leslie Corona, 415-600-5766, Email: CoronaLA@cpmcri.org about Study Merck 365

    Back to top

    Non-Metastatic Prostate Cancer

    Title: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
    Description: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male subjects 18 y/o and older with a pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate- to high-risk for recurrence
    Status: Please contact site for study status
    Contact: Andrea Davila, 415-600-1544, Email: DavilaA2@cpmcri.org about Study RTOG 0924

    Title: Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel
    Description: This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery.
    Investigator: Ari Baron, MD
    Eligibility: Patients with HCC who failed sorafenib, with documented PD or AEs that resulted in discontinuance of that agent.
    Status: Coming Soon
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Polaris NRG GU002

    • updated 03/2018

    Back to top